CS
NMTR

Credit Suisse’s 9 Meters Biopharma NMTR Stock Holding History

Credit Suisse’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-28
Closed – – 4447
2022
Q2 		$0 Buy
+28
New +$264 ﹤0.01% 4514
2019
Q3 		– Sell
-506
Closed -$11K – 4302
2019
Q2 		$11K Sell
506
-8
-2% -$240 ﹤0.01% 4056
2019
Q1 		$20K Buy
+514
New +$22.2K ﹤0.01% 3940

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Credit Suisse's NMTR Position: Q3 2022 in Review

Credit Suisse sold out of 9 Meters Biopharma (NMTR) in Q3 2022, closing a stake of 28 shares.

Credit Suisse first reported a position in NMTR in Q1 2019 and held it in 3 quarters. The position peaked at $20K in Q1 2019. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

  • Credit Suisse reported no remaining 9 Meters Biopharma position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 28 9 Meters Biopharma shares in Q3 2022.
  • Credit Suisse first reported a position in 9 Meters Biopharma in Q1 2019 and held it in 3 quarters.
  • Credit Suisse's 9 Meters Biopharma position peaked at $20K in Q1 2019.
  • 74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.